Cyp3a Inducers

Strong inducers of UGT1A1 decrease cabotegravir plasma concentrations and may result in loss of virologic response.

Concomitant use with strong CYP3A4 inducers decreases daridorexant exposure and may reduce efficacy. Concomitant use is not recommended.

Strong CYP3A inducers decrease DRSP exposure, leading to contraceptive failure and breakthrough bleeding. Avoid concomitant use.

Co-administration decreases ivosidenib plasma concentrations, reducing efficacy. Avoid concomitant use.

Strong CYP3A inducers significantly decrease lenacapavir plasma concentrations, resulting in loss of therapeutic effect and development of resistance.

Strong CYP3A inducers are contraindicated with lorlatinib. Concomitant use decreases lorlatinib plasma concentrations, which may decrease efficacy.

Concomitant use decreases lumateperone exposure. Avoid concomitant use with CAPLYTA.

Co-administration decreases mitapivat plasma concentrations, reducing efficacy of PYRUKYND. Avoid concomitant use.

Avoid concomitant use. Decreased sparsentan exposure, which may reduce efficacy.

Concomitant use reduces adagrasib exposure, which may reduce the effectiveness of KRAZATI.

Strong CYP3A4 inducers decrease alpelisib concentration, which may reduce alpelisib efficacy. Avoid concomitant use.

Coadministration decreases avapritinib plasma concentrations, which may decrease efficacy of AYVAKIT. Avoid coadministration.

Concomitant use decreases defactinib exposure, which may reduce the effectiveness of the drug combination. Avoid concomitant use.

Coadministration decreases bortezomib exposure which may decrease efficacy. Avoid concomitant use.

Avoid concomitant use. Decreases bosutinib Cmax and AUC, which may reduce BOSULIF efficacy.

Coadministration with strong CYP3A inducers decreased capmatinib exposure, which may decrease TABRECTA anti-tumor activity. Avoid coadministration.

Coadministration may decrease dasatinib concentrations and reduce efficacy. Consider alternative drugs or dasatinib dose increase.

Coadministration may decrease dexamethasone exposure, which may result in loss of efficacy. Avoid concomitant use or consider increasing the dose of dexamethasone.

CYP3A4 inducers may decrease rilpivirine plasma concentrations, resulting in loss of virologic response and possible resistance to rilpivirine or NNRTIs.

Strong CYP3A4 inducers decrease dordaviprone exposure, which may reduce the anti-tumor activity of MODEYSO. Avoid concomitant use.

Coadministration decreases duvelisib AUC, which may reduce COPIKTRA efficacy. Avoid coadministration.

CYP3A inducers increase clearance of elvitegravir and cobicistat, resulting in decreased plasma concentrations and potential loss of therapeutic effect or resistance.

Coadministration may result in decreased plasma concentrations of rilpivirine and loss of virologic response and possible resistance to rilpivirine or to the class of NNRTIs.

Coadministration may result in decreased plasma concentrations of RPV and loss of virologic response with possible resistance to RPV or NNRTIs.

Avoid concomitant use as it decreases finerenone exposure and may reduce efficacy of finerenone.

Co-administration decreases glasdegib plasma concentrations, potentially reducing efficacy. Avoid concomitant use.

Concomitant use decreases imlunestrant exposure, which may reduce effectiveness. Avoid concomitant use; if unavoidable, increase imlunestrant dosage.

Coadministration decreases ixabepilone plasma concentration, potentially decreasing efficacy. Avoid if possible; if unavoidable, increase IXEMPRA dose.

Concomitant use with strong CYP3A4 inducers decreases lazertinib concentrations, which may reduce the efficacy of lazertinib. Avoid concomitant use.

Strong CYP3A4 inducers decrease ribociclib plasma exposure, potentially reducing efficacy. Coadministration should be avoided.

Concomitant use is contraindicated. Strong inducers decrease mavorixafor Cmax and AUC, reducing drug effectiveness.

Concomitant use decreases nilotinib concentrations, which may reduce nilotinib efficacy. Avoid concomitant use.

Strong CYP3A4 inducers may decrease abiraterone concentrations, which may reduce the effectiveness of abiraterone.

Coadministration decreases AUC and Cmax of olanzapine and samidorphan, which may reduce LYBALVI efficacy. Concomitant use is not recommended.

Strong CYP3A inducers decrease olutasidenib Cmax and AUC, which may reduce REZLIDHIA efficacy. Avoid concomitant use.

Co-administration decreases osimertinib exposure, potentially reducing efficacy. Avoid concomitant use or increase osimertinib dose to 160 mg daily if unavoidable.

Decrease plasma concentration of oxycodone, resulting in decreased efficacy or withdrawal syndrome. Stopping inducers may cause serious respiratory depression.

Co-administration decreases palovarotene exposure, which may reduce effectiveness of SOHONOS. Avoid concomitant use.

Coadministration may decrease pazopanib plasma concentrations. Pazopanib not recommended with chronic use of strong CYP3A4 inducers.

Decreases pitolisant exposure by 50%, potentially reducing efficacy. Dosage adjustment required.

Concomitant use decreases pralsetinib exposure, which may decrease efficacy of GAVRETO. Avoid coadministration; if unavoidable, increase GAVRETO dose.

Concomitant use decreases remibrutinib exposure and may decrease efficacy. Avoid concomitant use.

Concomitant use may decrease repotrectinib plasma concentrations and reduce efficacy of AUGTYRO. Avoid concomitant use.

Strong CYP3A inducers decrease ribociclib plasma exposure. Avoid concomitant use and consider alternative medications.

Coadministration decreases ripretinib and active metabolite exposure, which may decrease anti-tumor activity. Avoid concomitant use.

Avoid JOURNAVX use with strong CYP3A inducers. Concomitant use results in reduced exposures of suzetrigine and M6-SUZ, which may result in reduced JOURNAVX efficacy.

Concomitant use decreases taletrectinib exposure, which may reduce the effectiveness of taletrectinib.

Concomitant use decreases tivozanib exposure, which may reduce FOTIVDA anti-tumor activity. Avoid concomitant use.

Reduces exposure to tolvaptan. Avoid concomitant use.

May decrease tretinoin plasma concentrations and reduce its efficacy. Avoid concomitant use if possible.

Concomitant use decreases tucatinib plasma concentrations, which may reduce TUKYSA activity.

Decreased exposure to valbenazine and active metabolite, potentially reducing efficacy. Concomitant use is not recommended.

Concomitant use may decrease vorasidenib plasma concentrations and reduce anti-tumor activity.

Coadministration decreases zanubrutinib Cmax and AUC, which may reduce BRUKINSA efficacy. Avoid coadministration; if unavoidable, increase dosage.

Avoid concomitant use. May decrease ziftomenib exposure and reduce efficacy of KOMZIFTI.

Strong CYP3A4 inducers decrease zongertinib exposure, which may reduce effectiveness of HERNEXEOS. Avoid concomitant use; if unavoidable, increase HERNEXEOS dose.

Concomitant use decreases zuranolone exposure and may reduce efficacy of ZURZUVAE. Avoid concomitant use.

UGT inducers can decrease acoramidis exposure. Avoid concomitant use.

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers.

CYP3A4 inducers may decrease amlodipine efficacy. Monitor blood pressure when coadministered.

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers due to potential decreased amlodipine efficacy.

Co-administration with amlodipine may reduce amlodipine efficacy. Closely monitor blood pressure when co-administered.

Strong CYP3A inducers decrease belumosudil exposure and may reduce efficacy. Increase REZUROCK dosage to 200 mg twice daily when used concomitantly.

Coadministration may decrease bendamustine plasma concentrations and decrease efficacy. Consider alternative therapies.

Prolonged or accelerated half-life of metronidazole or concomitant medications; use with caution.

Coadministration decreases brigatinib plasma concentrations, which may decrease the efficacy of ALUNBRIG. Coadministration should be avoided.

Concomitant use decreases buprenorphine plasma concentration, potentially resulting in decreased efficacy or withdrawal syndrome. Discontinuation may cause serious respiratory depression.

Concomitant use with CYP3A4 inducers is not recommended as the net effect on cariprazine exposure is unclear and effects have not been evaluated.

Concomitant use decreases crinecerfont exposure, which may reduce efficacy. Requires 2-fold increase in morning and evening dosage.

Co-administration may increase clearance of darunavir and cobicistat, resulting in lowered plasma concentrations and potential loss of therapeutic effect and development of resistance.

Concomitant use decreases deuruxolitinib exposure, which may reduce LEQSELVI efficacy. Avoid concomitant use.

Avoid concomitant use. May decrease dronedarone exposure and efficacy.

Inducers of CYP3A4 may decrease estrogen plasma concentration by increasing estrogen drug metabolism.

Strong CYP3A inducers decrease eliglustat concentrations, which may reduce CERDELGA efficacy. Coadministration should be avoided.

Coadministration decreases entrectinib plasma concentrations, which may reduce ROZLYTREK efficacy. Avoid coadministration.

Concomitant use of strong CYP3A inducers decreases eravacycline exposure, which may reduce efficacy. XERAVA dose increase required.

CYP3A4 inducers decrease haloperidol exposure and may reduce the effectiveness of haloperidol decanoate. Monitor patients and increase dosage if necessary.

CYP3A4 inducers may decrease imatinib C max and AUC; consider alternative agents.

Strong CYP3A4 inducers may decrease imatinib mesylate Cmax and AUC; consider alternative agents.

CYP inducers may cause accelerated half-life of metronidazole. Monitor for prolonged or accelerated drug effects.

CYP3A4 inducers may alter the first pass or clearance of nimodipine, potentially decreasing nimodipine levels.

Concomitant use may decrease paltusotine exposure and affect therapeutic response. May require PALSONIFY dosage increase up to three-fold or 120 mg daily, whichever is less.

Inducers may decrease phenobarbital exposure, reducing efficacy and increasing risk of breakthrough seizures. Closely monitor and consider dosage adjustment.

Inducers of CYP3A4 may decrease ruxolitinib systemic concentrations, potentially reducing efficacy.

Concomitant use decreases selpercatinib plasma concentrations, which may reduce anti-tumor activity. Avoid coadministration.

Monitor for loss of efficacy with moderate or strong CYP3A4 inducers in patients with CYP2C9*1/*3 or *2/*3 genotypes.

Co-administration may decrease sunitinib plasma concentrations. Consider dose increase of sunitinib malate.

CYP3A4 inducers may decrease tinidazole effect. Monitor for decreased tinidazole efficacy.

Can significantly decrease triazolam plasma concentration and may reduce effectiveness; caution recommended.

CYP3A inducers may decrease amlodipine efficacy. Blood pressure should be closely monitored when coadministered.

Concomitant use may decrease zolpidem exposure. Concomitant use is not recommended.

Potent CYP3A4 inducers may require close monitoring and dose adjustment of zonisamide and other CYP3A4 substrates.